COMPASS Pathways股价盘前飙涨30% 旗下抑郁症药物在二期后期试验中达成主要目标

美股速递
Feb 17

COMPASS Pathways plc(简称:COMPASS Pathways)股价在盘前交易中大幅上涨30%,此前该公司宣布其研发的抑郁症药物在第二项后期临床试验中成功达到主要研究终点。

这一积极结果显著提振了投资者信心,推动该生物技术公司股价在开盘前交易时段强势上扬。临床试验的成功意味着COMPASS Pathways在抑郁症治疗领域的创新药物向获得监管批准迈出了关键一步。

市场分析师指出,此次试验结果的突破性进展不仅验证了该药物的疗效,也为公司未来商业化前景注入了强劲动力。受此消息影响,医疗保健板块相关股票亦呈现跟涨态势。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10